Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,673 across all filing types
Latest filing 2026-05-24 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Regulatory Filings Classification · 91% confidence The document is a Form 6-K submitted to the SEC by a foreign private issuer (BioLineRx Ltd.) attaching a press release about clinical data announcements. It does not contain actual financial statements or management analysis, nor is it an AGM, earnings release, or share transaction. As an SEC compliance filing that reports a press release, it falls into the general “Regulatory Filings” category (RNS).
2026-05-24 English
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Report Publication Announcement Classification · 87% confidence The document is a short Immediate Report under Israeli securities regulations, stating that a Form 6-K report is attached (Form_6-K_24-May-26_isa.pdf) without including substantive content itself. Per the “menu vs meal” rule, it merely announces the publication of the report, so it should be classified as a Report Publication Announcement (RPA).
2026-05-24 English
6-K
Regulatory Filings
2026-05-22 English
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Regulatory Filings
2026-05-19 Hebrew (modern)
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Pat
Report Publication Announcement Classification · 90% confidence The document is an immediate report by BioLineRx (a Form 6-K filing) under Israeli and SEC rules, and it merely announces the publication of the detailed 6-K report (“Form_6-K_19-May-26_isa.pdf”) rather than containing substantive financial or operational data itself. It meets the “menu vs. meal” criteria for a Report Publication Announcement (RPA).
2026-05-19 English
6-K
Regulatory Filings
2026-05-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.